Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 PK Noninferiority Study of Subcutaneous Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria
2017-002370-39Phase 3Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ravulizumab in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Day 71 serum ravulizumab Ctrough. Started Nov 2018; status: terminated.
02
Drugs
ravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2017-002370-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002370-39.